Cipla is currently trading at Rs. 764.95, up by 2.30 points or 0.30% from its previous closing of Rs. 762.65 on the BSE.
The scrip opened at Rs. 769.95 and has touched a high and low of Rs. 770.75 and Rs. 763.10 respectively. So far 49613 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 814.45 on 10-Aug-2020 and a 52 week low of Rs. 356.75 on 13-Mar-2020.
Last one week high and low of the scrip stood at Rs. 780.40 and Rs. 757.00 respectively. The current market cap of the company is Rs. 61684.51 crore.
The promoters holding in the company stood at 36.68%, while Institutions and Non-Institutions held 39.92% and 23.40% respectively.
Cipla’s partner — Stempeutics Research has received regulatory approval by the Drug Controller General of India (DCGI) for the launch of Stempeucel in India. The product is indicated for the treatment of CLI due to Buerger’s Disease and Atherosclerotic Peripheral Arterial Disease. It is the first allogeneic cell therapy product to be approved for commercial use in India and the first stem cell product to be approved globally for CLI treatment.
The product has been developed by Stempeutics over a period of twelve years. The company’s proprietary pooling approach provides for an efficient manufacturing process thereby enabling the product to be made accessible to patients at an affordable cost. More than one million doses can be produced from a single set of master cell banks, which is unique in regenerative medicine, thus providing consistent product to patients. The proprietary technology also helps Stempeucel extend the therapeutic potential of the drug across multiple disease categories. Under the agreement signed between the two companies, Cipla has received exclusive rights to market and distribute the product in India by leveraging its expansive distribution strengths across the country.
Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.
